菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics


Speak with our Experts

Efficacy Studies

200+ Validated In Vivo Efficacy Models Across CDX/PBMC Humanized Models, Syngeneic Mouse Models, and More

At WuXi Biologics CRO Services, we offer efficacy studies with 200+ validated in vivo efficacy models across oncology, autoimmune, and metabolic diseases. Our 165 oncology efficacy models include syngeneic mouse models, CDX models, PBMC-based humanized mouse models, and IVIS imaging models for robust efficacy testing, with extensive expertise in TCE and ADC studies. For 36 autoimmune and metabolic disease models, we cover key indications such as IBD, diabetes, and related disorders.

CORE STRENGTH

In Vivo Pharmacology Service Highlights:

Broad Model Coverage

200+ validated in vivo models across major therapeutic areas

Diverse Oncology Models

165 efficacy models spanning syngeneic, CDX/PBMC, and IVIS platforms

Extensive Expertise in TCE & ADC

Proven efficacy pharmacology strategies for diverse modalities like TCE and ADC

Expert-guided Study Design

Science-driven approaches to maximize translational relevance and advance preclinical studies

Service Details

Efficacy Model Details

Efficacy models portfolio diagram spanning oncology, immunology, and metabolism. ↔ Flip for details
Efficacy Portfolio

Explore Our Efficacy Models

200+ validated in vivo models across oncology, immunology, and metabolism

01

16 Syngeneic Models

↔ Flip for details

  • Tumor models from diverse origins, including melanoma, prostate, skin, bladder, kidney, leukemia, breast, liver, lung, and colorectal
02

122 CDX/PBMC Models

↔ Flip for details

  • Tumor models from diverse origins, including pancreas, brain, breast, bone marrow, colon, cecum, connective tissue, leukemia, liver, lung, ovary, pharynx, kidney, prostate, skin, stomach, uterus/cervix, rectum, duodenum, myeloma, peripheral blood, and bladder
03

27 IVIS Imaging Models

↔ Flip for details

  • Imaging-enabled models from diverse origins, including lymphoma, leukemia, liver, lung, ovarian, melanoma, pancreas, prostate, breast, glioblastoma, and B-cell-related models
04

29 Autoimmune Disease Models

↔ Flip for details

  • Models covering key indications, including EAE, rheumatoid arthritis, asthma, SLE, IBD, air pouch, atopic dermatitis, psoriasis, fibrosis/liver injury, GvHD, TDAR, and LPS-induced acute inflammation
05

7 Metabolic Disease Models

↔ Flip for details

  • Models supporting diabetes, NASH, and cachexia studies
  • Deliverables: Tumor growth inhibition (TGI%) or disease symptom index, body weight, clinical observations, and IHC for target validation or immune profiling
  • Turnaround:6-10 weeks
Case Studies

Rational Study Design & In Vivo Efficacy Studies for ADCs and TCEs

Case Study 1: Rational CDX Model Design for More Predictable ADC Efficacy Data

This case study highlights how rational CDX model selection based on antigen expression can improve ADC efficacy predictability. In a high-antigen-expression CDX model, the ADC showed stronger dose-dependent tumor growth inhibition, while efficacy was reduced in a medium-expression model, supporting the importance of rational model design for translational assessment.

Case study: Rational CDX model design based on antigen expression for predictable ADC efficacy data.

Case Study 2: CDX/PBMC Humanized Model Enables In Vivo Evaluation of TCE Activity+

This case study highlights a CDX/PBMC humanized model for TCE efficacy studies. Severely immune-deficient mice were reconstituted with human PBMCs before CDX tumor cell inoculation, enabling target validation and in vivo assessment of dose-dependent anti-tumor activity for preclinical studies.

Case study: CDX/PBMC humanized model enabling in vivo evaluation of TCE activity.

Why WuXi Biologics

Why Work with WuXi Biologics for Efficacy Studies

  • Broad In Vivo Model Coverage: Access 200+ validated efficacy models across oncology, autoimmune, and metabolic diseases
  • Modality-Specific Model Selection: Extensive experience in model selection for TCE and ADC efficacy studies
  • Strong Oncology Platform: Support studies through syngeneic, CDX/PBMC, and IVIS imaging models
  • Biology-Driven Study Design: Tailored efficacy study strategies to match target biology, MOA, and project goals

Get Started

Move from Efficacy Models to Better Preclinical Decisions

Advance your program with WuXi Biologics’ preclinical efficacy study services designed to generate robust in vivo data across oncology, autoimmune, and metabolic disease models. From model selection and custom study design to translational readouts and decision-ready data reports, we help you characterize lead candidates to enhance translational relevance.